This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 11.90% and 10.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0% and 87.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -110.71% and 63.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -16.67% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of -9.09% and 16.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study
by Zacks Equity Research
Addex (ADXN) terminates the phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease. Shares fall.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -86.54% and 49.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -25.76% and 16.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0.00% and 96.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Addex Therapeutics Ltd. Sponsored ADR (ADXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 20th
by Zacks Equity Research
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -18.46% and 352.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.
J&J (JNJ) Recalls Some Sunscreens Due to Benzene Presence
by Zacks Equity Research
J&J (JNJ) withdraws five aerosol sunscreen products from the market due to "low levels" of benzene found in some samples.
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug
by Zacks Equity Research
Genocea Biosciences (GNCA) doses the first patient in phase I/IIa study on its investigational neoantigen-targeted T-Cell therapy, GEN-011, for solid tumors